A Study of Cytisinicline for Vaping Cessation in Adult Smokers

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
VapingE-Cig Use
Interventions
DRUG

cytisinicline

film-coated oral tablets containing 3 mg cytisinicline

DRUG

Placebo

film-coated oral tablets containing matched placebo

BEHAVIORAL

Behavioral support

Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.

Trial Locations (5)

14609

Rochester Clinical Research, Inc, Rochester

29405

Costal Carolina Research Center, North Charleston

37920

Alliance for Multispecialty Research, LLC, Knoxville

40509

Alliance for Multispecialty Research, LLC, Lexington

02114

Massachusetts General Hospital - Clinical Genetic Research Facility, Boston

Sponsors
All Listed Sponsors
lead

Achieve Life Sciences

INDUSTRY